Jorge Cortes, MD, Georgia Cancer Center, Augusta, GA, provides updates on the OPTIC study (NCT02467270), highlighting the benefits of adjusting the dosage of ponatinib based on treatment response for chronic-phase chronic myeloid leukemia (CP-CML). This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
